Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT00886444

Comparative Evaluation of Various Combinable Magnetic Resonance (CMR) Pulse-sequences for Macrophage Imaging Using Ferucarbotran

Comparative Evaluation of Various CMR Pulse-Sequences for Macrophage Imaging Using Ferucarbotran as Molecular Contrast Agent in Human Myocardial Infarction

Sponsor: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

Conditions Acute Myocardial Infarction

Interventions Ferucarbotran (Resovist)

Updated 6 times since 2017 Last updated: Nov 6, 2014 Started: Mar 31, 2009 Primary completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Acute Myocardial Infarction, this trial is completed. The trial is conducted by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) and has accumulated 6 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Aug 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

Data source: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stuttgart, Germany